Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 21.51 | Oscillator | Buy |
| Stochastic %K (14, 3, 3) | 5.66 | Oscillator | Buy |
| Williams %R (14) | -96.65 | Oscillator | Buy |
| MACD (12, 26, 9) | -12.34 (Hist -0.67) | Oscillator | Strong Sell |
| Average Directional Index (14) | 41.42 (+DI 13.8 / -DI 41.4) | Trend | Strong Sell |
| EMA 20 | 167.86 | MA | Strong Sell |
| SMA 20 | 168.24 | MA | Strong Sell |
| EMA 50 | 186.66 | MA | Strong Sell |
| SMA 50 | 191.85 | MA | Strong Sell |
| SMA 200 | 200.06 | MA | Strong Sell |
Current price $145.04
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 8, 26 | RBC Capital | maintain | Outperform | Outperform |
| Sep 29, 26 | Deutsche Bank | maintain | Buy | Buy |
| Sep 25, 26 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
| Sep 23, 26 | Truist Securities | maintain | Buy | Buy |
| Sep 18, 26 | Piper Sandler | maintain | Overweight | Overweight |
| Aug 31, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 12, 26 | Mizuho | maintain | Outperform | Outperform |
| Aug 11, 26 | Guggenheim | maintain | Buy | Buy |
| Aug 11, 26 | Wells Fargo | maintain | Overweight | Overweight |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 3, 26 | Jacobson Mark L. | officer: Chief Operating Officer | M-Exempt | 10,000 @ $12.95 | $129.5K |
| Sep 3, 26 | Jacobson Mark L. | officer: Chief Operating Officer | M-Exempt | 10,000 @ $12.95 | $129.5K |
| Sep 3, 26 | Jacobson Mark L. | officer: Chief Operating Officer | S-Sale | 10,000 @ $208.65 | $2.09M |
| Aug 5, 26 | Tabuteau Herriot | director, 10 percent owner, officer: Chief Executive Officer | M-Exempt | 45,004 @ $4.95 | $222.8K |
| Aug 6, 26 | Tabuteau Herriot | director, 10 percent owner, officer: Chief Executive Officer | M-Exempt | 4,660 @ $4.95 | $23.07K |
| Aug 5, 26 | Tabuteau Herriot | director, 10 percent owner, officer: Chief Executive Officer | S-Sale | 45,004 @ $212.01 | $9.54M |
| Aug 6, 26 | Tabuteau Herriot | director, 10 percent owner, officer: Chief Executive Officer | S-Sale | 4,660 @ $213.95 | $997.0K |
| Aug 5, 26 | Tabuteau Herriot | director, 10 percent owner, officer: Chief Executive Officer | M-Exempt | 45,004 @ $212.01 | $9.54M |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Sep 3, 2026 | 2026-09-03 19:09:24 | View |
| 10-Q | Aug 10, 2026 | 2026-08-10 16:07:28 | View |
| 8-K | Aug 10, 2026 | 2026-08-10 07:05:20 | View |
| 4 | Aug 7, 2026 | 2026-08-07 19:00:04 | View |
| SC 13G/A | Jul 27, 2026 | 2026-07-27 16:25:23 | View |
| 8-K | Jul 15, 2026 | 2026-07-15 07:05:15 | View |
| 4 | Jul 1, 2026 | 2026-07-01 19:30:11 | View |
| 4 | Jun 11, 2026 | 2026-06-11 20:34:11 | View |
| 4 | Jun 10, 2026 | 2026-06-10 21:49:45 | View |
| 4 | Jun 10, 2026 | 2026-06-10 21:49:38 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | AXSM | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -38.7x | -21.3x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -50.0x | EPS est. -2.90 | Elevated |
| Price / Book | 89.7x | 62.5x | Elevated |
| Price / Sales | 9.8x | 20.2x | Discount |
| EV / EBITDA | -42.6x | -22.3x | Elevated |
| Return on equity | -255.6% | — | Weak |
| Gross margin | 93.2% | 72.8% | Above hist. |
| Debt / Equity | 2.63 | 2.23 | Levered |
| Piotroski / Altman Z | 3/9 | Z 4.66 | Safe zone |
Discounted cash flow model
Stock news · updated daily
Axsome Therapeutics should expand its approved lineup while not facing the threat of generic competition through 2036. Eli Lilly is a leader in its core market and could diversify its lineup over the long run.
AXSM's Auvelity sales surged 54.2% to $333 million in the first half of 2026. New indications could further expand its growth potential.
Axsome sees at least $8 billion in potential peak Auvelity sales. Additional drugs and pipeline candidates could fuel long-term growth.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 10, 2026 | -0.89 | -0.99 | Miss -11.0% | $216.4M |
| May 4, 2026 | -0.85 | -1.26 | Miss -48.2% | $189.4M |
| Feb 23, 2026 | -0.70 | -0.71 | Miss -1.4% | $194.7M |
| Nov 3, 2025 | -0.82 | -0.94 | Miss -14.6% | $171.0M |
| Aug 4, 2025 | -1.00 | -0.92 | Beat 8.0% | $150.0M |
| May 5, 2025 | -1.26 | -1.22 | Beat 3.2% | $121.5M |